Escherichia coli: development of carbapenem resistance during therapy.

Tao Hong; Ellen Smith Moland; Baha Abdalhamid; Nancy D. Hanson; Jie Wang; Cindy Sloan; Diane Fabian; Awny Farajallah; Jerome Levine; Kenneth S. Thomson

doi:10.1086/429822

Escherichia coli: development of carbapenem resistance during therapy.

Tao Hong, Ellen Smith Moland, Baha Abdalhamid, Nancy D. Hanson, Jie Wang, Cindy Sloan, Diane Fabian, Awny Farajallah, Jerome Levine, Kenneth S. Thomson

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

Original language	English (US)
Pages (from-to)	e84-86
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	40
Issue number	10
DOIs	https://doi.org/10.1086/429822
State	Published - May 15 2005
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/429822

Cite this

@article{3e8b365735344172b95fa5735cd6cc69,

title = "Escherichia coli: development of carbapenem resistance during therapy.",

abstract = "A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.",

author = "Tao Hong and Moland, {Ellen Smith} and Baha Abdalhamid and Hanson, {Nancy D.} and Jie Wang and Cindy Sloan and Diane Fabian and Awny Farajallah and Jerome Levine and Thomson, {Kenneth S.}",

year = "2005",

month = may,

day = "15",

doi = "10.1086/429822",

language = "English (US)",

volume = "40",

pages = "e84--86",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Escherichia coli

T2 - development of carbapenem resistance during therapy.

AU - Hong, Tao

AU - Moland, Ellen Smith

AU - Abdalhamid, Baha

AU - Hanson, Nancy D.

AU - Wang, Jie

AU - Sloan, Cindy

AU - Fabian, Diane

AU - Farajallah, Awny

AU - Levine, Jerome

AU - Thomson, Kenneth S.

PY - 2005/5/15

Y1 - 2005/5/15

N2 - A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

AB - A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

UR - http://www.scopus.com/inward/record.url?scp=33646768702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646768702&partnerID=8YFLogxK

U2 - 10.1086/429822

DO - 10.1086/429822

M3 - Article

C2 - 15844056

AN - SCOPUS:33646768702

SN - 1058-4838

VL - 40

SP - e84-86

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - 10

ER -

Escherichia coli: development of carbapenem resistance during therapy.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this